BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gaviglio L, Gross A, Metzler-Nolte N, Ravera M. Synthesis and in vitro cytotoxicity of cis,cis,trans-diamminedichloridodisuccinatoplatinum(IV)-peptide bioconjugates. Metallomics 2012;4:260-6. [PMID: 22310724 DOI: 10.1039/c2mt00171c] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Johnstone TC, Wilson JJ, Lippard SJ. Monofunctional and higher-valent platinum anticancer agents. Inorg Chem 2013;52:12234-49. [PMID: 23738524 DOI: 10.1021/ic400538c] [Cited by in Crossref: 150] [Cited by in F6Publishing: 126] [Article Influence: 16.7] [Reference Citation Analysis]
2 Maschke M, Grohmann J, Nierhaus C, Lieb M, Metzler-nolte N. Peptide Bioconjugates of Electron-Poor Metallocenes: Synthesis, Characterization, and Anti-Proliferative Activity. ChemBioChem 2015;16:1333-42. [DOI: 10.1002/cbic.201500060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
3 Battistin F, Siegmund D, Balducci G, Alessio E, Metzler-Nolte N. Ru(ii)-Peptide bioconjugates with the cppH linker (cppH = 2-(2'-pyridyl)pyrimidine-4-carboxylic acid): synthesis, structural characterization, and different stereochemical features between organic and aqueous solvents. Dalton Trans 2019;48:400-14. [PMID: 30285015 DOI: 10.1039/c8dt03575j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
4 Novohradsky V, Zerzankova L, Stepankova J, Vrana O, Raveendran R, Gibson D, Kasparkova J, Brabec V. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands. J Inorg Biochem 2014;140:72-9. [PMID: 25063910 DOI: 10.1016/j.jinorgbio.2014.07.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
5 Huang R, Sun Y, Zhang X, Sun B, Wang Q, Zhu J. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery. Biomedicine & Pharmacotherapy 2015;73:116-22. [DOI: 10.1016/j.biopha.2015.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
6 Ma D, He H, Leung K, Chan DS, Leung C. Bioactive Luminescent Transition-Metal Complexes for Biomedical Applications. Angew Chem Int Ed 2013;52:7666-82. [DOI: 10.1002/anie.201208414] [Cited by in Crossref: 272] [Cited by in F6Publishing: 233] [Article Influence: 30.2] [Reference Citation Analysis]
7 Böhme D, Beck-Sickinger AG. Drug delivery and release systems for targeted tumor therapy. J Pept Sci 2015;21:186-200. [PMID: 25703117 DOI: 10.1002/psc.2753] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 10.0] [Reference Citation Analysis]
8 Han X, Sun J, Wang Y, He Z. Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy. Med Res Rev 2015;35:1268-99. [PMID: 26280923 DOI: 10.1002/med.21360] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
9 Ermondi G, Caron G, Ravera M, Gabano E, Bianco S, Platts JA, Osella D. Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum( iv ) complexes. Dalton Trans 2013;42:3482-9. [DOI: 10.1039/c2dt32360e] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 3.4] [Reference Citation Analysis]
10 Ong JX, Lim CSQ, Le HV, Ang WH. A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes. Angew Chem Int Ed Engl 2019;58:164-7. [PMID: 30407697 DOI: 10.1002/anie.201810361] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
11 Wilson JJ, Lippard SJ. Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev 2014;114:4470-95. [PMID: 24283498 DOI: 10.1021/cr4004314] [Cited by in Crossref: 393] [Cited by in F6Publishing: 317] [Article Influence: 43.7] [Reference Citation Analysis]
12 Fernández-moreira V, Herrera RP, Gimeno MC. Anticancer properties of gold complexes with biologically relevant ligands. Pure and Applied Chemistry 2019;91:247-69. [DOI: 10.1515/pac-2018-0901] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
13 Butler JS, Sadler PJ. Targeted delivery of platinum-based anticancer complexes. Current Opinion in Chemical Biology 2013;17:175-88. [DOI: 10.1016/j.cbpa.2013.01.004] [Cited by in Crossref: 186] [Cited by in F6Publishing: 156] [Article Influence: 20.7] [Reference Citation Analysis]
14 Meier SM, Novak M, Kandioller W, Jakupec MA, Arion VB, Metzler-Nolte N, Keppler BK, Hartinger CG. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. Chemistry 2013;19:9297-307. [PMID: 23712572 DOI: 10.1002/chem.201300889] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
15 Worm DJ, Els‐heindl S, Beck‐sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Peptide Science 2020;112. [DOI: 10.1002/pep2.24171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
16 Smiłowicz D, Metzler-Nolte N. Synthesis of monofunctional platinum(iv) carboxylate precursors for use in Pt(iv)-peptide bioconjugates. Dalton Trans 2018;47:15465-76. [PMID: 30334055 DOI: 10.1039/c8dt03082k] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
17 Ravera M, Gabano E, Pelosi G, Fregonese F, Tinello S, Osella D. A new entry to asymmetric platinum(IV) complexes via oxidative chlorination. Inorg Chem 2014;53:9326-35. [PMID: 25121398 DOI: 10.1021/ic501446b] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
18 Montagner D, Yap SQ, Ang WH. A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold. Angew Chem Int Ed Engl 2013;52:11785-9. [PMID: 24105908 DOI: 10.1002/anie.201305734] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
19 Mckeon AM, Noonan J, Devocelle M, Murphy BM, Griffith DM. Platinum( iv ) oxaliplatin–peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells. Chem Commun 2017;53:11318-21. [DOI: 10.1039/c7cc04764a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 3.2] [Reference Citation Analysis]
20 Johnstone TC, Suntharalingam K, Lippard SJ. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev 2016;116:3436-86. [PMID: 26865551 DOI: 10.1021/acs.chemrev.5b00597] [Cited by in Crossref: 1125] [Cited by in F6Publishing: 995] [Article Influence: 187.5] [Reference Citation Analysis]
21 Kenny RG, Chuah SW, Crawford A, Marmion CJ. Platinum(IV) Prodrugs - A Step Closer to Ehrlich's Vision?: Platinum(IV) Prodrugs - A Step Closer to Ehrlich's Vision? Eur J Inorg Chem 2017;2017:1596-612. [DOI: 10.1002/ejic.201601278] [Cited by in Crossref: 84] [Cited by in F6Publishing: 53] [Article Influence: 16.8] [Reference Citation Analysis]
22 Wu Z, Martinez-Fong D, Trédaniel J, Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol (Lausanne) 2012;3:184. [PMID: 23335914 DOI: 10.3389/fendo.2012.00184] [Cited by in Crossref: 29] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
23 Mitra K, Lyons CE, Hartman MCT. A Platinum(II) Complex of Heptamethine Cyanine for Photoenhanced Cytotoxicity and Cellular Imaging in Near-IR Light. Angew Chem Int Ed Engl 2018;57:10263-7. [PMID: 29939482 DOI: 10.1002/anie.201806911] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
24 Sheikh AH, Khalid A, Khan F, Begum A. Fluorescent Gadolinium(III)-Oligopeptide Complexes and Carbon Nanotube Composite as Dual Modality Anticancer Agents. ChemistrySelect 2019;4:228-35. [DOI: 10.1002/slct.201802810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
25 Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020;8:571. [PMID: 32733853 DOI: 10.3389/fchem.2020.00571] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
26 Huang G, Chen S, Qin Q, Luo J, Tan M, Wang Z, Zou B, Liang H. In vitro and in vivo activity of novel platinum( ii ) complexes with naphthalene imide derivatives inhibiting human non-small cell lung cancer cells. New J Chem 2019;43:8146-52. [DOI: 10.1039/c9nj01076a] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Massaguer A, González-Cantó A, Escribano E, Barrabés S, Artigas G, Moreno V, Marchán V. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides. Dalton Trans 2015;44:202-12. [PMID: 25369773 DOI: 10.1039/c4dt02710h] [Cited by in Crossref: 53] [Cited by in F6Publishing: 10] [Article Influence: 7.6] [Reference Citation Analysis]
28 Montagner D, Yap SQ, Ang WH. A Fluorescent Probe for Investigating the Activation of Anticancer Platinum(IV) Prodrugs Based on the Cisplatin Scaffold. Angew Chem 2013;125:12001-5. [DOI: 10.1002/ange.201305734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
29 Ravera M, Gabano E, Mcglinchey MJ, Osella D. A view on multi-action Pt(IV) antitumor prodrugs. Inorganica Chimica Acta 2019;492:32-47. [DOI: 10.1016/j.ica.2019.04.025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 11.3] [Reference Citation Analysis]
30 Kenny RG, Marmion CJ. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens? Chem Rev 2019;119:1058-137. [PMID: 30640441 DOI: 10.1021/acs.chemrev.8b00271] [Cited by in Crossref: 220] [Cited by in F6Publishing: 172] [Article Influence: 73.3] [Reference Citation Analysis]
31 Mitra K, Lyons CE, Hartman MCT. A Platinum(II) Complex of Heptamethine Cyanine for Photoenhanced Cytotoxicity and Cellular Imaging in Near-IR Light. Angew Chem 2018;130:10420-4. [DOI: 10.1002/ange.201806911] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Teles CM, Antunes VU, Cardoso RS, Candido TZ, Lima CS, Ruiz ALT, Juliano MA, Favaro DC, Abbehausen C. Functionalization of new anticancer Pt(II) complex with transferrin receptor binding peptide. Inorganica Chimica Acta 2020;511:119811. [DOI: 10.1016/j.ica.2020.119811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Ravera M, Gabano E, Tinello S, Zanellato I, Osella D. May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs? J Inorg Biochem 2017;167:27-35. [PMID: 27898344 DOI: 10.1016/j.jinorgbio.2016.11.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
34 Gross A, Habig D, Metzler-nolte N. Synthesis and Structure-Activity Relationship Study of Organometallic Bioconjugates of the Cyclic Octapeptide Octreotate. ChemBioChem 2013;14:2472-9. [DOI: 10.1002/cbic.201300450] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
35 Gutiérrez A, Gimeno MC, Marzo I, Metzler-nolte N. Synthesis, Characterization, and Cytotoxic Activity of Au I N,S-Heterocyclic Carbenes Derived from Peptides Containing L -Thiazolylalanine: Studies on Au I N,S-Heterocyclic Carbenes Derived from Peptides. Eur J Inorg Chem 2014;2014:2512-9. [DOI: 10.1002/ejic.201402103] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
36 Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012;2012:967347. [PMID: 23316341 DOI: 10.1155/2012/967347] [Cited by in Crossref: 198] [Cited by in F6Publishing: 191] [Article Influence: 19.8] [Reference Citation Analysis]
37 Monney A, Albrecht M. Transition metal bioconjugates with an organometallic link between the metal and the biomolecular scaffold. Coordination Chemistry Reviews 2013;257:2420-33. [DOI: 10.1016/j.ccr.2012.12.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
38 Gabano E, Ravera M, Tinello S, Osella D. Synthesis of Pt IV -Biomolecule Conjugates through Click Chemistry: Synthesis of Pt IV -Biomolecule Conjugates through Click Chemistry. Eur J Inorg Chem 2015;2015:5335-41. [DOI: 10.1002/ejic.201501066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
39 Ong JX, Lim CSQ, Le HV, Ang WH. A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes. Angew Chem 2019;131:170-3. [DOI: 10.1002/ange.201810361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
40 Klein AV, Hambley TW. Platinum-Based Anticancer Agents. In: Storr T, editor. Ligand Design in Medicinal Inorganic Chemistry. Chichester: John Wiley & Sons, Ltd; 2014. pp. 9-45. [DOI: 10.1002/9781118697191.ch2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
41 Xu Z, Wang Z, Yiu SM, Zhu G. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity. Dalton Trans 2015;44:19918-26. [PMID: 26514681 DOI: 10.1039/c5dt03101j] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
42 Wilson JJ, Lippard SJ. Oxidative Reactivity and Cytotoxic Properties of a Platinum(II) Complex Prepared by Outer-Sphere Amide Bond Coupling. Polyhedron 2013;58:71-8. [PMID: 24489429 DOI: 10.1016/j.poly.2012.07.097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
43 Wang X, Wang X, Guo Z. Functionalization of Platinum Complexes for Biomedical Applications. Acc Chem Res 2015;48:2622-31. [PMID: 26247558 DOI: 10.1021/acs.accounts.5b00203] [Cited by in Crossref: 180] [Cited by in F6Publishing: 162] [Article Influence: 25.7] [Reference Citation Analysis]
44 Albada B, Metzler-nolte N. Organometallic–Peptide Bioconjugates: Synthetic Strategies and Medicinal Applications. Chem Rev 2016;116:11797-839. [DOI: 10.1021/acs.chemrev.6b00166] [Cited by in Crossref: 130] [Cited by in F6Publishing: 85] [Article Influence: 21.7] [Reference Citation Analysis]
45 Ma D, He H, Leung K, Chan DS, Leung C. Bioaktive lumineszierende Übergangsmetallkomplexe für biomedizinische Anwendungen. Angew Chem 2013;125:7820-37. [DOI: 10.1002/ange.201208414] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
46 Predarska I, Saoud M, Morgan I, Eichhorn T, Kaluđerović GN, Hey-Hawkins E. Cisplatin-cyclooxygenase inhibitor conjugates, free and immobilised in mesoporous silica SBA-15, prove highly potent against triple-negative MDA-MB-468 breast cancer cell line. Dalton Trans 2021. [PMID: 34877948 DOI: 10.1039/d1dt03265h] [Reference Citation Analysis]
47 Alessio M, Zanellato I, Bonarrigo I, Gabano E, Ravera M, Osella D. Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells. Journal of Inorganic Biochemistry 2013;129:52-7. [DOI: 10.1016/j.jinorgbio.2013.09.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
48 Fadzen CM, Wolfe JM, Zhou W, Cho CF, von Spreckelsen N, Hutchinson KT, Lee YC, Chiocca EA, Lawler SE, Yilmaz OH, Lippard SJ, Pentelute BL. A Platinum(IV) Prodrug-Perfluoroaryl Macrocyclic Peptide Conjugate Enhances Platinum Uptake in the Brain. J Med Chem 2020;63:6741-7. [PMID: 32410451 DOI: 10.1021/acs.jmedchem.0c00022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
49 Alexander C, Nithyakumar A, Arockia Samy N. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: Syntheses, characterization, and in vitro cytotoxicity studies. Inorganic Chemistry Communications 2017;78:17-20. [DOI: 10.1016/j.inoche.2017.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Medrano MA, Morais M, Ferreira VFC, Correia JDG, Paulo A, Santos I, Navarro-ranninger C, Valdes AA, Casini A, Mendes F, Quiroga AG. Nonconventional trans -Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytototoxicity Studies: Nonconventional trans -Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytototoxicity Studies. Eur J Inorg Chem 2017;2017:1835-40. [DOI: 10.1002/ejic.201700072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
51 Moreira T, Francisco R, Comsa E, Duban-Deweer S, Labas V, Teixeira-Gomes AP, Combes-Soia L, Marques F, Matos A, Favrelle A, Rousseau C, Zinck P, Falson P, Garcia MH, Preto A, Valente A. Polymer "ruthenium-cyclopentadienyl" conjugates - New emerging anti-cancer drugs. Eur J Med Chem 2019;168:373-84. [PMID: 30826512 DOI: 10.1016/j.ejmech.2019.02.061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]